Guogen Shan, Xinlin Lu, Zhigang Li, Jessica Z K Caldwell, Charles Bernick, Jeffrey Cummings
{"title":"ADSS：检测阿尔茨海默病病情进展的综合评分。","authors":"Guogen Shan, Xinlin Lu, Zhigang Li, Jessica Z K Caldwell, Charles Bernick, Jeffrey Cummings","doi":"10.3233/ADR-230043","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Composite scores have been increasingly used in trials for Alzheimer's disease (AD) to detect disease progression, such as the AD Composite Score (ADCOMS) in the lecanemab trial.</p><p><strong>Objective: </strong>To develop a new composite score to improve the prediction of outcome change.</p><p><strong>Methods: </strong>We proposed to develop a new composite score based on the statistical model in the ADCOMS, by removing duplicated sub-scales and adding the model selection in the partial least squares (PLS) regression.</p><p><strong>Results: </strong>The new <b>AD</b> composite <b>S</b>core with variable <b>S</b>election (ADSS) includes 7 cognitive sub-scales. ADSS can increase the sensitivity to detect disease progression as compared to the existing total scores, which leads to smaller sample sizes using the ADSS in trial designs.</p><p><strong>Conclusions: </strong>ADSS can be utilized in AD trials to improve the success rate of drug development with a high sensitivity to detect disease progression in early stages.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10894615/pdf/","citationCount":"0","resultStr":"{\"title\":\"ADSS: A Composite Score to Detect Disease Progression in Alzheimer's Disease.\",\"authors\":\"Guogen Shan, Xinlin Lu, Zhigang Li, Jessica Z K Caldwell, Charles Bernick, Jeffrey Cummings\",\"doi\":\"10.3233/ADR-230043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Composite scores have been increasingly used in trials for Alzheimer's disease (AD) to detect disease progression, such as the AD Composite Score (ADCOMS) in the lecanemab trial.</p><p><strong>Objective: </strong>To develop a new composite score to improve the prediction of outcome change.</p><p><strong>Methods: </strong>We proposed to develop a new composite score based on the statistical model in the ADCOMS, by removing duplicated sub-scales and adding the model selection in the partial least squares (PLS) regression.</p><p><strong>Results: </strong>The new <b>AD</b> composite <b>S</b>core with variable <b>S</b>election (ADSS) includes 7 cognitive sub-scales. ADSS can increase the sensitivity to detect disease progression as compared to the existing total scores, which leads to smaller sample sizes using the ADSS in trial designs.</p><p><strong>Conclusions: </strong>ADSS can be utilized in AD trials to improve the success rate of drug development with a high sensitivity to detect disease progression in early stages.</p>\",\"PeriodicalId\":73594,\"journal\":{\"name\":\"Journal of Alzheimer's disease reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10894615/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's disease reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/ADR-230043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/ADR-230043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
ADSS: A Composite Score to Detect Disease Progression in Alzheimer's Disease.
Background: Composite scores have been increasingly used in trials for Alzheimer's disease (AD) to detect disease progression, such as the AD Composite Score (ADCOMS) in the lecanemab trial.
Objective: To develop a new composite score to improve the prediction of outcome change.
Methods: We proposed to develop a new composite score based on the statistical model in the ADCOMS, by removing duplicated sub-scales and adding the model selection in the partial least squares (PLS) regression.
Results: The new AD composite Score with variable Selection (ADSS) includes 7 cognitive sub-scales. ADSS can increase the sensitivity to detect disease progression as compared to the existing total scores, which leads to smaller sample sizes using the ADSS in trial designs.
Conclusions: ADSS can be utilized in AD trials to improve the success rate of drug development with a high sensitivity to detect disease progression in early stages.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
